Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. has launched a Phase 1 clinical study titled ‘AN ...
Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) ...
Phathom will showcase its growing leadership in GI through multiple engagements with the medical and scientific community, including a product theater presentation highlighting VOQUEZNA ® (vonoprazan) ...
BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...
(Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI ® (enzalutamide), in combination with leuprolide ...
Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
In 2023, the 7MM (seven major markets) PCSK9 inhibitors market was valued at approximately USD 2 billion, with the United States leading at around USD 900 million. That year, roughly 640,000 cases of ...
The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and cluster headaches in adults, Amneal Pharmaceuticals announced Thursday. The ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as ...
Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression New post-hoc analysis of CAPLYTA® (lumateperone) Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback